The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AGIOS PHARMACEUTICALS, INC. | COM | 00847X104 | 29,131,350 | 785,000 | SH | SOLE | 785,000 | 0 | 0 | ||
| ALUMIS INC. | COM | 022307102 | 119,529,434 | 4,247,670 | SH | SOLE | 4,247,670 | 0 | 0 | ||
| ArriVent BioPharma, Inc. | COM | 04272N102 | 10,468,586 | 301,341 | SH | SOLE | 301,341 | 0 | 0 | ||
| AtaiBeckley Inc. | COM | 04650F101 | 14,492,500 | 2,750,000 | SH | SOLE | 2,750,000 | 0 | 0 | ||
| Aura Biosciences, Inc. | COM | 05153U107 | 9,466,671 | 1,333,334 | SH | SOLE | 1,333,334 | 0 | 0 | ||
| Beam Therapeutics Inc. | COM | 07373V105 | 11,325,600 | 330,000 | SH | SOLE | 330,000 | 0 | 0 | ||
| Celldex Therapeutics, Inc. | COM | 15117B202 | 32,734,121 | 879,713 | SH | SOLE | 879,713 | 0 | 0 | ||
| CG Oncology, Inc. | COM | 156944100 | 168,358,233 | 2,369,574 | SH | SOLE | 2,369,574 | 0 | 0 | ||
| Corvus Pharmaceuticals, Inc. | COM | 221015100 | 27,358,621 | 1,831,233 | SH | SOLE | 1,831,233 | 0 | 0 | ||
| Crinetics Pharmaceuticals, Inc. | COM | 22663K107 | 7,933,414 | 212,010 | SH | SOLE | 212,010 | 0 | 0 | ||
| Denali Therapeutics Inc. | COM | 24823R105 | 35,924,950 | 1,396,771 | SH | SOLE | 1,396,771 | 0 | 0 | ||
| Disc Medicine, Inc. | COM | 254604101 | 70,946 | 970 | SH | SOLE | 970 | 0 | 0 | ||
| GH Research PLC | ORD | G3855L106 | 25,280,452 | 940,493 | SH | SOLE | 940,493 | 0 | 0 | ||
| Hinge Health, Inc. | CL A | 433313103 | 18,293,200 | 220,400 | SH | SOLE | 220,400 | 0 | 0 | ||
| Jade Biosciences, Inc. | COM | 008064206 | 19,701,741 | 886,667 | SH | SOLE | 886,667 | 0 | 0 | ||
| Kailera Therapeutics, Inc. | COM | 482931102 | 826,125 | 37,500 | SH | SOLE | 37,500 | 0 | 0 | ||
| Kymera Therapeutics, Inc. | COM | 501575104 | 16,779,890 | 146,332 | SH | SOLE | 146,332 | 0 | 0 | ||
| Minerva Neurosciences, Inc. | COM | 603380205 | 11,019,991 | 1,985,584 | SH | SOLE | 1,985,584 | 0 | 0 | ||
| Parabilis Medicines, Inc. | COM | 698955101 | 27,343,834 | 999,044 | SH | SOLE | 999,044 | 0 | 0 | ||
| Research Alliance Corp III | CL A | G75226103 | 3,210,000 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| Seaport Therapeutics, Inc. | COM | 81221K108 | 38,651,196 | 1,779,521 | SH | SOLE | 1,779,521 | 0 | 0 | ||
| Verastem, Inc. | COM | 92337C203 | 12,020,130 | 3,146,631 | SH | SOLE | 3,146,631 | 0 | 0 | ||
| Zura Bio Ltd | CL A | G9TY5A101 | 2,655,000 | 450,000 | SH | SOLE | 450,000 | 0 | 0 | ||